Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: Association with protein kinase Cδ

Blood

Volumn 100, Issue 10, 2002, Pages 3741-3748

  Ringshausen, Ingo ^a   Schneller, Folker ^a   Bogner, Christian ^a   Hipp, Susanne ^a   Duyster, Justus ^a   Peschel, Christian ^a   Decker, Thomas ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; INHIBITOR OF APOPTOSIS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN MCL 1; PROTEIN P70; ROTTLERIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0037111661     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0539     Document Type: Article

References (61)

1. O'Bien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 1995;85:306-318.
2. Meinhardt G, Wendtner CM, Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: Factors and signaling pathways regulating cell growth and survival. J Mol Med. 1999;77:282-293.
3. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
4. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol. 1998;25:11-18.
5. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82:1820-1828.
6. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-3389.
7. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT)1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997;100:3140-3148.
8. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-κB activity and apoptosis in chronic lymphocytic leukemia. J Immunol. 2000;164:2200-2206.
9. Domin J, Waterfield MD. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett. 1997;410:91-95.
10. Andjelic S, Hsia C, Suzuki H, Kadowaki T, Koyasu S, Liou HC. Phosphatidylinositol 3-kinase and NF-kappa B/Rel are at the divergence of CD40 mediated proliferation and survival pathways. J Immunol. 2000;165:3860-3867.
11. Aagaard-Tillery KM, Jelinek DF. Phosphatidylinositol 3-kinase activation in normal human B lymphocytes. J Immunol. 1996;156:4543-4554.
12. Alessi DR, Andejelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15:6541-6551.
13. Aoki M, Schetter C, Himly M, Batista O, Chang HW, Vogt PK. The catalytic subunit of phosphoinositide 3-kinase: Requirements for oncogenicity. J Biol Chem. 2000;275:6267-6275.
14. Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinase, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A. 1992;89:9267-9271.
15. Sun M, Wang G, Paciga JE, et al. Akt1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001;159:431-437.
16. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res. 1999;253:210-229.
17. Romashkova JA, Makarov SS. NF-κB is a target of Akt in anti-apoptotic PDGF signaling. Nature. 1999;401:86-90.
18. Aoki M, Blazek E, Vogt K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3K and Akt. Proc Natl Acad Sci U S A. 2001;98:136-141.
19. 3. J Biol Chem. 1994;69:32358-32367.
20. Popoff IJ, Deans JP. Activation and tyrosine phosphorylation of proteinkinase Cδ in response to B cell antigen receptor stimulation. Mol Immunol. 1999;36:1005-1016.
21. Ettinger SL, Lauener RW, Duronio V. Protein kinase Cδ specifically associates with phosphathidyinositol 3-kinase following cytokine stimulation. J Biol Chem. 1996;271:14514-14518.
22. Ashton AW, Watanabe G, Albanese C, Harrington EO, Ware JA, Pestell RG. Protein kinase Cδ inhibition of S-phase transition in capillary endothelial cell involves the cyclin-dependent kinase inhibitor p27. J Biol Chem. 1999;274:20805-20811.
23. Watanabe T, Ono Y, Taniyama Y, Hazama K, et al. Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-δ subspecies. Proc Natl Acad Sci U S A. 1992;89:10159-10163.
24. Fukumoto S, Nishizawa Y, Hosoi M, et al. Protein kinase Cδ inhibits the proliferation of vascular smooth muscle cells by suppressing G1 cyclin expression. J Biol Chem. 1997;272:13816-13822.
25. Miyamoto A, Nakayama K, Imaki H, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ. Nature. 2002;416:865-869.
26. Emoto Y, Manome G, Meinhard G, et al. Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J. 1995;14:6148-6156.
27. Skorski T, Kanakarai P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BRC/ABL and is required for growth of Philadelphia chromosome-positive cells. Blood. 1995;86:726-736.
28. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol-3 kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994;269:5241-5248.
29. Pettitt AR, Moran EC, Cawley JC. Homotypic interactions protect chronic lymphocytic leukemia cells from spontaneous death in vitro. Leuk Res. 2001;25:1003-1012.
30. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270;1326-1331.
31. Lali FV, Hunt AE, Turner SJ, Foxwell B. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation and retinoblastoma hyperphosphorylation in interleukin-2 stimulated T-cells independently of p38 MAP kinase. J Biol Chem. 2000;275:7395-7402.
32. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995;92:7686-7689.
33. Pullen N, Thomas G. The molecular phosphorylation and activation of p70S6kinase. FEBS Lett. 1997;410:78-82.
34. Pronk GJ, Ramer K, Amiri P, Williams LT. Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER. Science. 1996;271:808-810.
35. Bellosillo B, Dalmau M, Colomer D, Gil J. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood. 1997;89:3378-3384.
36. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell death proteases. Nature. 1997;388:300-304.
37. Gold MR, Scheid MP, Santos L, et al. The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase. J Immunol. 1999;163:1894-1905.
38. Gschwendt M, Muller HJ, Kielbassa K, et al. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun. 1994;199:93-98.
39. Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Mueller HJ, Johannes FJ. Inhibition of protein kinase Cμ by various inhibitors: differentiation from protein kinase c isoenzymes. FEBS Lett. 1996;392:77-80.
40. Benekli M, Xia Z, Donohue KA, et al. Constitutive activation of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002;99:252-257.
41. Tse KF, Mukheriee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2000;14:1766-1776.
42. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108:851-859.
43. Fruman DA, Snapper SB, Yballe CM, et al. Impaired B cell development and proliferation in absence of phosphoinositide 3 kinase p85α. Science. 1999;283:393-397.
44. Imani F, Rager KJ, Catipovic B, Marsh DG. Interleukin-4 (IL-4) induces phosphatidylinositol 3 kinase (p85) dephosphorylation: Implications for the role of SHP-1 in the IL-4-induced signals in human B cells. J Biol Chem. 1997;272:7927-7931.
45. Barragan M, Bellosillo B, Campas C, Colomer D, Pons G, Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia. Blood. 2002;99:2969-2976.
46. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restaining the phophoinositol-3 kinase/AKT pathway. Proc Natl Acad Sci U S A. 1999;96:4240-4245.
47. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol-3 kinase/Akt pathway in multiple myeloma plasma cells: Role in cytokine-dependent survival and proliferation responses. Cancer Res. 2000;60:6763-6770.
48. Wickremasinghe RG, Ganeshaguru K, Jones DT, et al. Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukemia cells. Br J Haematol. 2001;114:608-615.
49. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of antigen receptor. Blood. 2001;98:3050-3057.
50. Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein kinase C isotypes controlled by phosphoinositide 3 kinase through the protein kinase PDK1. Science 1998;281:2042-2045.
51. Stempka L, Girod A, Muller HJ, et al. Phosphorylation of protein kinase Cδ (PKCδ) at threonine 505 is not a prerequisite for enzymatic activity: Expression of rat PKCdelta and an alanine 505 mutant in bacteria in a functional form. J Biol Chem. 1997;272:6805-6811.
52. Gschwendt M, Kielbassa K, Kittstein W, Marks F. Tyrosine phosphorylation and stimulation of protein kinase Cδ from porcine spleen by src in vitro: Dependence on the activated state of protein kinase Cδ. FEBS Lett. 1994;347:85-89.
53. Jain N, Zhang T, Kee WH, Li W, Cao X. Protein kinase Cδ associates with phosphorylates Stat3 in an interleukin-6 dependent manner. J Biol Chem. 1999;274:24392-24400.
54. Vancurova I, Miskolci V, Davidson D. NF-κB activation in tumor necrosis factor α-stimulated neutrophils is mediated by protein kinase Cδ: Correlation to nuclear Ikappa Balpha. J Biol Chem. 2001;276:19746-19752.
55. Forbes IJ, Zalewski PD, Giannakis C, Cowled PA. Induction of apoptosis in CLL and its prevention by phorbol ester. Exp Cell Res. 1992;198:367-372.
56. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-CLL. Br J Haematol. 1999;106:995-1004.
57. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiddol and 7-hydroxystaurosporine down-regulate antiapoptosis proteins in B-CLL. Blood. 2000;96:393-397.
58. Goldman JM, Druker BJ. Chronic myeloid leukemia: Current treatment options. Blood. 2001;98:2039-2042.
59. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol. 2001;19:1485-1492.
60. Meyer T, Regenass U, Fabbro D, et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer. 1989;43:851-859.
61. Varterasian ML, Mohammad RM, Shurafa S, et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2000;6:825-828.